伐昔洛韦在预防母胎巨细胞病毒传播中的疗效新数据
这项回顾性多中心研究评估了妊娠期母体原发性巨细胞病毒感染后使用伐昔洛韦8 g/日预防母胎传播的疗效与安全性,共纳入143例患者(伐昔洛韦组59例,未治疗对照组84例)。倾向评分校正分析显示伐昔洛韦治疗与母胎传播率总体降低显著相关(OR 0.40,95%CI 0.18-0.90;P=0.029),在孕早期和孕中期原发感染中可能有效,母体副作用多为轻度且非特异性。
要点
- 伐昔洛韦8 g/日与母胎CMV传播总体降低显著相关(OR 0.40,95%CI 0.18-0.90;P=0.029)。
- 孕早期原发感染传播率伐昔洛韦组22%(8/36)vs 对照组41%(19/46),P=0.068。
- 孕中期原发感染传播率伐昔洛韦组25%(2/8)vs 对照组52%(14/27),P=0.244。
核心结论
- 研究提示,对妊娠期原发性CMV感染的孕妇使用伐昔洛韦治疗可降低母胎CMV传播风险,且可能在孕早期和孕中期原发感染病例中有效。
研究设计与样本
- 回顾性、多中心研究,最终分析纳入143例患者,伐昔洛韦组59例(8 g/日)与未治疗对照组84例,每例均经病毒学检测确认母体原发感染并准确确定感染起始时间,主要结局为出生时经唾液、尿液和/或血液样本聚合酶链反应分析诊断的先天性CMV感染,采用倾向评分校正的逻辑回归分析评估疗效。
诊断标准与关键数值
- 主要结局为出生时经唾液、尿液和/或血液样本聚合酶链反应分析诊断的先天性CMV感染;倾向评分校正分析显示伐昔洛韦治疗与母胎CMV传播总体降低显著相关(OR 0.40,95%CI 0.18-0.90;P=0.029);出生时母胎CMV传播率伐昔洛韦组vs对照组:围受孕期原发感染7%(1/14)vs 10%(1/10)(P=1.00),孕早期原发感染22%(8/36)vs 41%(19/46)(P=0.068),孕中期原发感染25%(2/8)vs 52%(14/27)(P=0.244);按治疗开始时母体病毒血症分析,病毒血症阳性者伐昔洛韦组21% vs 对照组43%(P=0.072),病毒血症阴性者伐昔洛韦组22% vs 对照组17%(P=0.659)。
临床应用与阅片要点
- 作者认为,对妊娠期原发性CMV感染的孕妇使用伐昔洛韦治疗可降低母胎CMV传播风险,且可能在孕早期和孕中期原发感染病例中有效;母体伐昔洛韦相关副作用多数为轻度且非特异性。
局限性
- 本研究为回顾性研究。
- 孕早期原发感染传播率伐昔洛韦组22%(8/36)vs 对照组41%(19/46)未达统计学显著(P=0.068)。
- 孕中期原发感染传播率伐昔洛韦组25%(2/8)vs 对照组52%(14/27)未达统计学显著(P=0.244)。
- 病毒血症阳性者传播率伐昔洛韦组21% vs 对照组43%仅呈趋势(P=0.072),未达统计学显著。
- 病毒血症阴性者传播率伐昔洛韦组22% vs 对照组17%无显著差异(P=0.659)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic hearing and neurological deficits. The aim of our study was to evaluate the efficacy and safety of valacyclovir (VCV) treatment in preventing CMV transmission to the fetus after maternal primary infection.
METHODS: This was a retrospective, multicenter study evaluating the rate of maternal-fetal CMV transmission in pregnancies with maternal primary CMV infection treated with VCV at a dosage of 8 g per day (VCV group) compared with a control group of untreated women. Each case underwent virological testing to confirm maternal primary infection and to provide accurate dating of onset of infection. The primary outcome was the presence of congenital CMV infection at birth diagnosed based on polymerase chain reaction analysis of saliva, urine and/or blood samples. The efficacy of VCV treatment was assessed using logistic regression analysis adjusted for a propensity score.
RESULTS: In total, 143 patients were included in the final analysis, of whom 59 were in the VCV group and 84 were in the untreated control group. On propensity-score-adjusted analysis, VCV treatment was significantly associated with an overall reduction in the rate of maternal-fetal CMV transmission (odds ratio, 0.40 (95% CI, 0.18-0.90); P = 0.029). The rate of maternal-fetal CMV transmission, determined at birth, in the VCV vs control group was 7% (1/14) vs 10% (1/10) after periconceptional maternal primary infection (P = 1.00), 22% (8/36) vs 41% (19/46) after first-trimester maternal primary infection (P = 0.068) and 25% (2/8) vs 52% (14/27) after second-trimester maternal primary infection (P = 0.244). When analyzing the efficacy of VCV treatment according to maternal viremia at treatment initiation, there was a trend towards greater efficacy when patients were viremia-positive (21% vs 43%; P = 0.072) compared with when they were viremia-negative (22% vs 17%; P = 0.659). Maternal side effects associated with VCV were mild and non-specific in most cases.
CONCLUSION: Our findings indicate that VCV treatment of pregnant women with primary CMV infection reduces the risk of maternal-fetal transmission of CMV and may be effective in cases with primary infection in the first and second trimesters. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Egloff C, Sibiude J, Vauloup-Fellous C, et al. New data on efficacy of valacyclovir in secondary prevention of maternal-fetal transmission of cytomegalovirus. Ultrasound Obstet Gynecol. 2023. PMID: 35900718. doi:10.1002/uog.26039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。